Clinical Trials Logo

Peripartum Cardiomyopathy clinical trials

View clinical trials related to Peripartum Cardiomyopathy.

Filter by:

NCT ID: NCT05878041 Recruiting - Clinical trials for Peripartum Cardiomyopathy

Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.

PPCMREGISTRY
Start date: February 21, 2024
Phase:
Study type: Observational [Patient Registry]

Peripartum cardiomyopathy (PPCM) is a rare, severe and potentially life-threatening disorder of largely unknown etiology and pathophysiology, with unexplained geographical differences and heterogeneous presentation. Investigators hypothesize that a network-based multidisciplinary strategy integrating clinical and molecular phenotyping of PPCM patients might anticipate diagnosis, optimize treatments, and identify novel mechanisms to achieve the unmet goal of personalized medicine.

NCT ID: NCT04927715 Recruiting - Clinical trials for Peripartum Cardiomyopathy

Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.

Start date: February 20, 2021
Phase:
Study type: Observational

this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.

NCT ID: NCT04234659 Recruiting - Cardiogenic Shock Clinical Trials

PPCM Observational Study (Peripartum Cardiomyopathy)

Start date: January 11, 2021
Phase:
Study type: Observational

The purpose of this study is to examine the clinical treatment of patients diagnosed with peripartum cardiomyopathy complicated by cardiogenic shock.

NCT ID: NCT04144660 Completed - Cardiogenic Shock Clinical Trials

"Treatment Use of ECMO In Pregnancy or Peripartum Patient."

Start date: October 28, 2019
Phase:
Study type: Observational

The goal of this study is to describe the use of ECMO (Extracorporeal Membrane Oxygenation) in the pregnant or peripartum patient.

NCT ID: NCT04143997 Withdrawn - Clinical trials for Diastolic Dysfunction

Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery

Start date: November 1, 2019
Phase:
Study type: Observational

The purpose of this project is to evaluate parameters of diastolic dysfunction assessed by clinical echocardiogram in patients who have had recovery of systolic function.

NCT ID: NCT04049136 Completed - Obesity Clinical Trials

NT-proBNP Levels and Obesity in Pregnancy

Start date: July 15, 2019
Phase:
Study type: Observational

A screening modality to help categorize obese pregnant women as high or low probability for heart failure would be helpful in the evaluation of the obese pregnant women with dyspnea. Outside of pregnancy, measurement of brain natriuretic peptide (BNP) or amino-terminal pro-brain natriuretic peptide (NT-proBNP) is recommended in the evaluation of acute dyspnea and in the diagnosis of heart failure. During pregnancy, elevated BNP has been associated with adverse cardiovascular events, while normal BNP levels have been observed in healthy pregnancies. While BNP levels outside of pregnancy have been shown to be lower in obese patients variations in BNP levels by body mass index (BMI) in pregnancy have not been studied. Before BNP can be deemed a reliable screening test for heart failure in obese pregnant women, normal BNP values in the setting of obesity and pregnancy need to be established. We therefore propose the following specific aims: Objective 1: Compare mean plasma NT-proBNP levels in the third trimester, immediately postpartum, and at 4-6 weeks postpartum between obese pregnant women without cardiovascular disease and non-obese pregnant women without cardiovascular disease. We hypothesize that mean plasma NT-proBNP levels in obese pregnant women without pre-existing cardiovascular disease will be significantly lower than levels in non-obese pregnant women. Objective 2: Assess whether plasma NT-proBNP levels in pregnancy correlate with BMI. We hypothesize that there will be an inverse correlation between plasma NT-proBNP levels and BMI in our pregnant cohort similar to that seen outside of pregnancy.

NCT ID: NCT03907267 Completed - Clinical trials for Peripartum Cardiomyopathy

Taurine in Peripartum Cardiomyopathy

Start date: January 1, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Taurine as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

NCT ID: NCT03364140 Recruiting - Clinical trials for Peripartum Cardiomyopathy

A Registry of Peripartum Cardiomyopathy in Turkey

Start date: July 2, 2017
Phase: N/A
Study type: Observational

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality of young women. Its' etiology, epidemiology and treatment is not yet well described. This will be a retrospective, national, multicenter observational study, conducted in Turkey. It is expected that approximately 50 women with PPCM will be recorded.

NCT ID: NCT03081949 Completed - Clinical trials for Peripartum Cardiomyopathy

Peripartum Cardiomyopathy in Nigeria Registry

PEACE
Start date: June 12, 2017
Phase: Phase 4
Study type: Interventional

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality, and Nigeria probably has the highest burden of the disease in the world. Unfortunately, much about the disease including its aetiology, epidemiology and treatment is not yet well described. This will be a prospective, national, multicenter cohort study, conducted in centres in Nigeria. It is expected that approximately 500 patients with PPCM and 500 apparently healthy pregnant women will be recruited over a 6-month period with follow-up at 3-monthly intervals for 18 months.

NCT ID: NCT02590601 Withdrawn - Clinical trials for Peripartum Cardiomyopathy

Bromocriptine in the Treatment of Peripartum Cardiomyopathy

BRO-HF
Start date: January 1, 2017
Phase: Phase 3
Study type: Interventional

Peripartum cardiomyopathy (PPCM) is a rare, but significant heart disease affecting young women in the puerperal period. Thus far, no specific treatment has been approved to treat this disease. PPCM has a wide spectrum of clinical manifestations ranging from mild heart failure to severe cardiomyopathy, cardiogenic shock and death. A significant proportion of survivors have persistent chronic heart failure leading to disabling symptoms and decreased quality of life. Animal studies have suggested that prolactin is central to the development of PPCM. Prolactin has pro-inflammatory and anti-angiogenic effects that may promote PPCM. Bromocriptine, a central dopamine agonist known to decrease prolactin levels, might thwart its deleterious effects in women suffering from PPCM. Following this rationale, bromocriptine should improve myocardial function in women suffering from PPCM and thus, improve cardiovascular outcomes and healthcare outcomes.